comprehensive -WSS

comprehensive

author：comprehensive 2025-10-04 03:59:26 - browse：523

Illustration of a laptop on top of a TV with a hand sticking out, holding a newspaper. -- coverage from STAT — Adobe

WASHINGTON – If you live in this city, you’re probably awash in pharmacy benefit manager ads — whether you’re listening to an NPR podcast, reading the New York Times, streaming “Yellowstone,” or watching the U.S. Open Golf Championships. It doesn’t matter if it’s 5 a.m., primetime, or 11 p.m.; in between ads for dog joint supplements and the “Barbie” movie, you will inevitably learn about these middlemen of the prescription drug market.

Ads eviscerating and glorifying PBMs have been around for years. But they’ve intensified over the past three months as Congress scrutinizes PBMs’ role in shaping high drug prices. Over a half-dozen U.S. House and Senate Committees have started investigating PBMs, advancing bipartisan legislation to increase transparency in the industry; ban PBMs from charging more for a drug than what they pay (and pocketing the difference); and require them to pass all fees, rebates, and other payments they receive to insurers.

Lobbying groups have responded to this legislative push with dueling campaigns in the court of public opinion. On one side is the Pharmaceutical Care Management Association, the trade association representing PBMs, which argues that pharmaceutical companies are responsible for high drug prices. On the other side is the industry group PhRMA, which points the finger right back, saying that PBMs are really to blame. Both trade associations have launched ad campaigns worth millions of dollars, blanketing TV, radio, social media, print, and beyond.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： What to know about 'Guardians of the Galaxy Vol. 3' as it hits Disney+

focus

WSS

Judge in Trump's Jan. 6 case gives attorneys 2 weeks to propose trial date

Jesse Tyler Ferguson makes friendship bracelets for Taylor Swift's Eras Tour

What to know about 'Guardians of the Galaxy Vol. 3' as it hits Disney+

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

Buoyed by wins on obesity, Novo Nordisk eyes heart disease

Slain Parkland victim's father speaks out following reenactment

knowledge

comprehensive

hotspot

Sports medicine is finally prioritizing gender equality

Jailed Russian opposition leader Alexey Navalny gets 19 more years in prison

What does generative AI mean for health care? We asked experts

Prosecutors seek bail revocation for FTX founder Sam Bankman

Duchenne breakthrough therapy leaves behind pioneering families

New company forms to vet health AI models, root out weaknesses

After affirmative action ruling, medical educators look to 'holistic review'

Congress must reauthorize a committee to support older Americans

In age of alternative facts, a scholarly course on calling out crap

In key trial, Verve's treatment lowers cholesterol levels in patients

knowledge

Readout LOUD podcast: A CRISPR milestone, biotech mixology

Jailed Russian opposition leader Alexey Navalny gets 19 more years in prison

Buoyed by wins on obesity, Novo Nordisk eyes heart disease

Anthos stroke drug appears safer than common blood thinner

Flash flooding emergencies prompt evacuations in Kentucky, Tennessee

Calls for Trump's election interference trial to be televised part of long debate

hotspot

focus

focus

leisure time